

News Release

CATTI and Cell and Gene Therapy Catapult partner to establish international best practice standards in advanced therapies manufacturing training

October 12, 2023 (London, United Kingdoms), (Montreal, Canada) -- The Canadian Advanced Therapies Training Institute (CATTI) and Cell and Gene Therapy Catapult (CGT Catapult) have entered into an agreement to advance regenerative medicine, including cell and gene therapy training locally and globally. Both institutions have agreed to the development of joint activities to address issues of mutual interest. The ultimate goal is to establish international best practice standards in advanced therapies manufacturing training.

Both CATTI and CGT Catapult are addressing a critical need by creating highly-qualified personnel (HQP) who are certified under Good Manufacturing Practices (GMP) and qualified for workflow under aseptic conditions to manufacture cancer immunotherapies, cell and gene therapies, vaccines and other biotherapeutic applications.

“CATTI has a wealth of experience developing and delivering industry-leading biomanufacturing training programmes. By exchanging ideas and learnings with the experts at CATTI, we hope to establish best practice in skills and training. CATTI is an excellent partner for us at CGT Catapult and we look forward to building this relationship and applying the insights gained to strengthen our skills and training offering for the advanced therapy industry,” says Matthew Durdy, Chief Executive of CGT Catapult.

The partnership will allow CATTI to access a wider network of subject matter experts through the CGT Catapult to support and accelerate the development of CATTI programs for the North American market.

CATTI’s CEO Vanessa Laflamme noted, “CATTI is pleased to work in collaboration with CGT Catapult, as they are recognized as a world leader and a model for training in advanced therapies. Making sure that our training curriculum is built on industry-recognized international standards has always been an important goal for CATTI, and partnering with CGT Catapult brings a tremendous gain in strengthening our training curriculum.”

About CATTI

The Canadian Advanced Therapies Training Institute (CATTI) is developing and scaling e-learning and on-site GMP training programs for efficient and rapid upskilling of the biomanufacturing workforce required in Canada and internationally. CATTI’s goals are to fill the dearth in available talent of HQP trained and qualified for workflow under aseptic conditions and bridge the gap

between the academic background qualifications and the market readiness of HQP. For more information, visit catti.ca.

About Cell and Gene Therapy Catapult

The Cell and Gene Therapy Catapult is an independent innovation and technology organisation committed to the advancement of cell and gene therapies with a vision of a thriving industry delivering life changing advanced therapies to the world. Its aim is to create powerful collaborations which overcome challenges to the advancement of the sector. The Cell and Gene Therapy Catapult works with Innovate UK. For more information, please visit <https://ct.catapult.org.uk/> or <https://www.ukri.org/councils/innovate-uk/>.

For more information, please contact:

CATTI

Valerie Roussin-Paradis, Director of Business Development & Partnership

Email: v.r.paradis@catti.ca

FTI Consulting for the Cell and Gene Therapy Catapult

George Kendrick +44 (0) 203 727 1411 / George.Kendrick@fticonsulting.com

Alexander Davis +44 (0) 203 727 1729 / Alexander.Davis@fticonsulting.com